-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pfizer recently announced that the U.
Prevnar 20 was approved through the priority review process
It is worth mentioning that this is the first approval of a conjugate vaccine that can prevent most invasive pneumococcal diseases and pneumonia caused by 20 serotypes, of which 7 cause 40% of pneumococcal disease cases and deaths in the United States
This approval is based on data from Pfizer’s adult clinical program, which includes phase 1 and phase 2 trials, and 3 phase 3 trials (NCT03760146, NCT03828617, NCT03835975), which evaluated the safety and immunogenicity of Prevnar 20 Sex
Note: The original text has been deleted
This article is from Bio Valley, for more information, please download the Bio Valley APP (http://